Physician profile
David Moreno
NPI 1225045156
$4,653.92
in general payments reported to CMS, 2019-2025
29 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $887 · 2021: $667 · 2022: $872 · 2023: $458 · 2024: $656 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $740.44 | 2019-2025 | Mounjaro, Kisunla, Emgality |
| Novo Nordisk INC | $696.42 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $576.83 | 2019-2025 | Airsupra, Farxiga |
| Aytu Biopharma, INC. | $427.19 | 2020 | |
| Corcept Therapeutics | $368.95 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $368.32 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.70 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $197.41 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $141.48 | 2023-2025 | Cologuard Collection Kit |
| Medtronic Vascular, INC. | $110.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.05 | 2019-2023 | Xifaxan |
| Pfizer INC. | $99.00 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $71.84 | 2022-2024 | Quviviq |
| Allergan, INC. | $69.44 | 2019-2020 | |
| Abbott Laboratories | $52.38 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $48.87 | 2020-2021 | |
| Abbvie INC. | $46.82 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $38.57 | 2025 | Recorlev |
| Merck Sharp & Dohme LLC | $37.30 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.79 | 2019 | |
| Dexcom, INC. | $24.37 | 2023 | Dexcom G6 Transmitter |
| Clarus Therapeutics INC. | $23.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.26 | 2022 | |
| Amgen INC. | $18.74 | 2020 | |
| Neurocrine Biosciences, INC. | $16.45 | 2023 | Ongentys, Ingrezza |
| Antares Pharma, INC. | $14.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.75 | 2021 | |
| Esperion Therapeutics, INC. | $13.37 | 2021 | |
| Therapeuticsmd, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.